Objective: To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients.
Material And Method: 364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 anti-Spike protein IgG and neutralizing antibody 2 months following vaccination were measured by ELIZA.
Results: Injection site pain and fever were the most common local and systemic side effects. The overall seroconversion rate was 86.9% that was lower in older age, those with hematological malignancies and chemotherapy receivers.
Conclusion: The result of study confirmed the safety and short-term efficacy of inactivated vaccine in patients with malignancies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567287 | PMC |
http://dx.doi.org/10.1080/07357907.2021.1992420 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!